Drug Information

Drug General Information
Drug ID
D00NUG
Former ID
DNCL001641
Drug Name
Olokizumab
Drug Type
Monoclonal antibody
Indication Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] Phase 2 [523674]
Company
UCB
Target and Pathway
Target(s) Interleukin-6 Target Info Modulator [544437]
KEGG Pathway Cytokine-cytokine receptor interaction
HIF-1 signaling pathway
FoxO signaling pathway
PI3K-Akt signaling pathway
Toll-like receptor signaling pathway
NOD-like receptor signaling pathway
Cytosolic DNA-sensing pathway
Jak-STAT signaling pathway
Hematopoietic cell lineage
TNF signaling pathway
Intestinal immune network for IgA production
Non-alcoholic fatty liver disease (NAFLD)
Prion diseases
Salmonella infection
Pertussis
Legionellosis
Chagas disease (American trypanosomiasis)
African trypanosomiasis
Malaria
Amoebiasis
Tuberculosis
Hepatitis B
Measles
Influenza A
HTLV-I infection
Herpes simplex infection
Pathways in cancer
Transcriptional misregulation in cancer
Inflammatory bowel disease (IBD)
Rheumatoid arthritis
Graft-versus-host disease
Hypertrophic cardiomyopathy (HCM)
NetPath Pathway IL1 Signaling Pathway
TWEAK Signaling Pathway
TCR Signaling Pathway
IL2 Signaling Pathway
IL4 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
TNFalpha Signaling Pathway
Alpha6Beta4Integrin Signaling Pathway
TSLP Signaling Pathway
Leptin Signaling Pathway
RANKL Signaling Pathway
IL5 Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Pathway Interaction Database LPA receptor mediated events
IL27-mediated signaling events
Validated transcriptional targets of AP1 family members Fra1 and Fra2
SHP2 signaling
Glucocorticoid receptor regulatory network
amb2 Integrin signaling
ATF-2 transcription factor network
AP-1 transcription factor network
IL6-mediated signaling events
IL23-mediated signaling events
Reactome Interleukin-6 signaling
MAPK3 (ERK1) activation
MAPK1 (ERK2) activation
Senescence-Associated Secretory Phenotype (SASP)
WikiPathways Toll-like receptor signaling pathway
SIDS Susceptibility Pathways
TCR Signaling Pathway
Senescence and Autophagy in Cancer
Cytokines and Inflammatory Response
IL-6 signaling pathway
Myometrial Relaxation and Contraction Pathways
Hematopoietic Stem Cell Differentiation
Differentiation Pathway
Interleukin-6 signaling
Spinal Cord Injury
Adipogenesis
TNF alpha Signaling Pathway
TSLP Signaling Pathway
TWEAK Signaling Pathway
Folate Metabolism
Vitamin B12 Metabolism
Selenium Micronutrient Network
Regulation of toll-like receptor signaling pathway
References
Ref 523674ClinicalTrials.gov (NCT01463059) Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy. U.S. National Institutes of Health.
Ref 544437Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 September; 73(9): 1607-1615.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.